QNCX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QNCX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Quince Therapeutics's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Quince Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Quince Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Quince Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Quince Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Quince Therapeutics is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Quince Therapeutics (NAS:QNCX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Quince Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dirk Thye | director, officer: Chief Executive Officer | 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Brendan Hannah | officer: Chief Business Officer | 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Charles S. Ryan | officer: President | C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790 |
David Lamond | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Guenter Janhofer | officer: Chief Scientific Officer | 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080 |
Luca Benatti | director | C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011 |
Margaret Mcloughlin | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Ted Monohon | officer: Chief Accounting Officer | C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107 |
June Bray | director | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
Caryn Gordon Mcdowell | officer: Chief Legal & Adm. Officer | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Philip S Low | director | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Karen L. Smith | officer: Chief Medical Officer | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Marwan Sabbagh | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Stephen S. Dominy | director, officer: Chief Scientific Officer | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105 |
Christopher P. Lowe | officer: Chief Financial Officer | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
From GuruFocus
By Business Wire • 06-25-2024
By Business Wire • 05-06-2024
By Business Wire • 02-04-2025
By Business Wire • 02-05-2025
By Business Wire • 02-22-2024
By Business Wire • 11-11-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 09-03-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.